Neoadjuvant Targeted Therapy and Consolidative Surgery

Chapter
Part of the Current Clinical Urology book series (CCU)

Abstract

Approximately 30–40% of patients with renal cell carcinoma present with locally advanced or metastatic disease. With improved response rates and tolerability of targeted agents, the concept of primary targeted therapy followed by consolidative surgery has emerged as a potential paradigm for management of select patients with locally advanced RCC. This strategy may help facilitate less morbid resection of high risk surgical disease and improve outcomes of nephron-sparing surgery for bulky or locally extensive tumors. Herein, we discuss patient selection criteria, assess the emerging data for this approach, and highlight perioperative patient safety concerns, arguments for and against utilization of primary systemic targeted therapy, and future directions for investigation.

References

  1. 1.
    Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98:1331–4.PubMedCrossRefGoogle Scholar
  2. 2.
    van der Veldt AA, Meijerink MR, van den Eertwegh AJ, et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res. 2008;14:2431–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol. 2006;24:5601–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Wood CG, Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer. 2009;115 Suppl 10:2355–60.PubMedCrossRefGoogle Scholar
  6. 6.
    Margulis V, Wood CG. Pre-surgical targeted molecular therapy in renal cell carcinoma. BJU Int. 2009;103:150–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Bex A, van der Veldt AA, Blank C, et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol. 2009;27:533–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Cost NG, Delacroix Jr, SE, Sleeper JP, et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011;59:912–8.Google Scholar
  9. 9.
    Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res. 2007;13:697s–702.PubMedCrossRefGoogle Scholar
  10. 10.
    Shuch B, Riggs SB, LaRochelle JC, et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 2008;102(6):692–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Silberstein JL, Millard F, Mehrazin R, et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int. 2010;106:1270–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Samplaski MK, Zhou M, Lane BR, Herts B, Campbell SC. Renal mass sampling: an enlightened perspective. Int J Urol. 2011;18:5–19.PubMedCrossRefGoogle Scholar
  13. 13.
    Li G, Cuilleron M, Cottier M, et al. The use of MN/CA9 gene expression in identifying malignant solid renal tumors. Eur Urol. 2006;49:401–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Valera VA, Li-Ning TE, Walter BA, Roberts DD, Linehan WM, Merino MJ. Protein expression profiling in the spectrum of renal cell carcinomas. J Cancer. 2010;1:184–96.PubMedCrossRefGoogle Scholar
  15. 15.
    Bukowski RM. Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma. Cancer Manag Res. 2011;3:273–85.PubMedCrossRefGoogle Scholar
  16. 16.
    van der Veldt AA, Boven E, Helgason HH, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer. 2008;99:259–65.PubMedCrossRefGoogle Scholar
  17. 17.
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRefGoogle Scholar
  18. 18.
    Robert G, Gabbay G, Bram R, et al. Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol. 2009;55:1477–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol. 2009;181:518–23.PubMedCrossRefGoogle Scholar
  20. 20.
    Cowey CL, Amin C, Pruthi RS, et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol. 2010;28:1502–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Powles T, Kayani I, Blank C, et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol. 2011;22:1041–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.PubMedCrossRefGoogle Scholar
  23. 23.
    Karakiewicz PI, Suardi N, Jeldres C, et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol. 2008;53:845–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Ansari J, Doherty A, McCafferty I, Wallace M, Deshmukh N, Porfiri E. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma. Clin Genitourin Cancer. 2009;7:E39–41.PubMedCrossRefGoogle Scholar
  25. 25.
    Weight CJ, Larson BT, Fergany AF, et al. Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses. J Urol. 2010;183:1317–23.PubMedCrossRefGoogle Scholar
  26. 26.
    Jonasch E, Wood CG, Matin SF, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:4076–81.PubMedCrossRefGoogle Scholar
  27. 27.
    Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005;91(3):173–80.PubMedCrossRefGoogle Scholar
  28. 28.
    Hong MH, Kim HS, Kim C, et al. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat. 2009;41:67–72.PubMedCrossRefGoogle Scholar
  29. 29.
    Margulis V, Matin SF, Tannir N, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008;180:94–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006;95:581–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Pfizer. Highlights of prescribing information. New York; 2006. http://www.pfizer.com/files/products/uspi_sutent.pdf. Accessed 6 Feb 2011.
  33. 33.
    Pfizer. Temsirolimus [prescribing information]. Madison, NJ; 2008. http://www.pfizerpro.com/content/showlabeling.asp?id=490. Accessed 6 Feb 2011
  34. 34.
    Biswas S, Kelly J, Eisen T. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Oncologist. 2009;14:52–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of Urology, Department of SurgeryMoores UCSD Cancer Center, University of California San Diego School of MedicineLa JollaUSA

Personalised recommendations